A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients

References

• Jost WH, Bäumer T, Laskawi R, et al. Therapy of sialorrhea with botulinum neurotoxin. Neurol Ther. 2019;8(2):273–288. Epub 2019 Sep 21. PMID: 31542879; PMCID: PMC6858891.
   PubMed Web of Science ®Google Scholar
• Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5(5):1010–1031. PMID: 23698357; PMCID: PMC3709276.
   PubMed Web of Science ®Google Scholar
• Dias BL, Fernandes AR, Maia Filho HS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J). 2016;92(6):549–558. Epub 2016 Jun 6. PMID: 27281791.
   PubMed Web of Science ®Google Scholar
• Crysdale WS. Management options for the drooling patient. Ear Nose Throat J. 1989;68(820):825–826. 829–30. PMID: 2612390.
   Google Scholar
• Blasco PA, Allaire JH. Drooling in the developmentally disabled: management practices and recommendations. Consortium on drooling. Dev Med Child Neurol. 1992;34(10):849–862. PMID: 1397726.
   PubMed Web of Science ®Google Scholar
• van Hulst K, van den Engel-Hoek L, Geurts ACH, et al. Development of the Drooling Infants and Preschoolers Scale (DRIPS) and reference charts for monitoring saliva control in children aged 0-4 years. Infant Behav Dev. 2018;50:247–256. Epub 2018 Feb 12. PMID: 29448187.
   PubMed Web of Science ®Google Scholar
• Khan WU, Campisi P, Nadarajah S, et al. Botulinum toxin A for treatment of sialorrhea in children: an effective, minimally invasive approach. Arch Otolaryngol Head Neck Surg. 2011;137(4):339–344. Epub 2011 Jan 17. PMID: 21242533.
   PubMedGoogle Scholar
• Van Hulst K, Van Der Burg JJ, Jongerius PH, et al. Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities. Dev Med Child Neurol. 2020;62(3):354–362. Epub 2019 Nov 14. PMID: 31729034; PMCID: PMC7028146.
   PubMed Web of Science ®Google Scholar
• Riva A, Federici C, Piccolo G, et al. Exploring treatments for drooling in children with neurological disorders. Expert Rev Neurother. 2021;21(2):179–187. Epub 2020 Dec 6. PMID: 33222543.
   PubMed Web of Science ®Google Scholar
• Steffen A, Jost W, Bäumer T, et al. Hypersalivation: update of the German S2k guideline (AWMF) in short form. J Neural Transm (Vienna). 2019;126(7):853–862. Epub 2019 Apr 10. PMID: 30972507.
   PubMed Web of Science ®Google Scholar
• Hockstein NG, Samadi DS, Gendron K, et al. Sialorrhea: a management challenge. Am Fam Physician. 2004;69:2628–2634. PMID: 15202698.
   PubMed Web of Science ®Google Scholar
• Chang SC, Lin CK, Tung LC, et al. The association of drooling and health-related quality of life in children with cerebral palsy. Neuropsychiatr Dis Treat. 2012;8:599–604. Epub 2012 Dec 11. PMID: 23251093; PMCID: PMC3523561.
   PubMed Web of Science ®Google Scholar
• Glader L, Delsing C, Hughes A, et al. Sialorrhea in cerebral palsy. 2018. Available at: https://www.aacpdm.org/publications/care-pathways/sialorrhea[Lastaccessed03May2021]
   Google Scholar
• National Institute for Health and Care Excellence. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide. Evidence summary. 2017 Feb 14. [cited 2021 May 17]. Available at: https://www.nice.org.uk/advice/es5/chapter/Introduction-and-current-guidance.
   Google Scholar
• Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1–9. PMID: 25559581; PMCID: PMC4359186.
   PubMed Web of Science ®Google Scholar
• Jost WH. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease. J Neural Transm (Vienna). 2016;123(1):51–55. Epub 2015 Jul 3. PMID: 26138438.
   PubMed Web of Science ®Google Scholar
• Solstice Neurosciences LLC. MYOBLOC® (rimabotulinumtoxinB) injection, for intramuscular or intraglandular use. 2000. Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103846s5190lbl.pdf[Lastaccessed17May2021]
   Google Scholar
• Jost WH. Treatment of drooling in Parkinson’s disease with botulinum toxin. Mov Disord. 1999;14(6):1057. PMID: 10584695.
   PubMed Web of Science ®Google Scholar
• Bekkers S, Delsing CP, Kok SE, et al. Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities. Neurology. 2019;92:e1195–e1204. Epub 2019 Feb 6. PMID: 30728311.
   PubMedGoogle Scholar
• Lungren MP, Halula S, Coyne S, et al. Ultrasound-guided botulinum toxin type A salivary gland injection in children for refractory sialorrhea: 10-year experience at a large tertiary children’s hospital. Pediatr Neurol. 2016;54:70–75. Epub 2015 Sep 28. PMID: 26706481.
   PubMed Web of Science ®Google Scholar
• Loens S, Brüggemann N, Steffen A, et al. Localization of salivary glands for botulinum toxin treatment: ultrasound versus landmark guidance. Mov Disord Clin Pract. 2020;7(2):194–198. PMID: 32071939; PMCID: PMC7011800.
   PubMed Web of Science ®Google Scholar
• Vashishta R, Nguyen SA, White DR, et al. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013;148(2):191–196. Epub 2012 Oct 30. PMID: 23112272.
   PubMed Web of Science ®Google Scholar
• Jost WH, Friedman A, Michel O, et al. SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982–e1991. Epub 2019 Mar 27. PMID: 30918101; PMCID: PMC6511076.
   PubMed Web of Science ®Google Scholar
• Jost WH, Friedman A, Michel O, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020;70:23–30. Epub 2019 Nov 26. PMID: 31794936.
   PubMed Web of Science ®Google Scholar
• Berweck S, Bonikowski M, Kim H, et al. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI. Neurology. 2021 Aug 2:10.1212/WNL.0000000000012573. Epub ahead of print. PMID: 34341153.
   Google Scholar
• Berweck S, Kim H, Banach M, et al. Efficacy of incobotulinumtoxinA in the treatment of 6–17-year-old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Poster presented at TOXINS 2021 Virtual Conference; 16–17 January 2021.
   Google Scholar
• Berweck S, Bonikowski M, Banach M, et al. Efficacy and safety of incobotulinumtoxinA in the treatment of 2–5-year-old children with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Poster presented at TOXINS 2021 Virtual Conference; 16–17 January 2021.
   Google Scholar
• Merz Pharmaceutical, LLC. XEOMIN- incobotulinumtoxina injection, powder, lyophilized, for solution. 2020. Prescribing information. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccdc3aae-6e2d-4cd0-a51c-8375bfee9458&type=display[Lastaccessed26April2021]
   Google Scholar
• Merz Pharma UK Ltd. Xeomin 100 units powder for solution for injection. Summary of prescribing information. 2020. [cited 2021 Apr 26]. Available at: https://www.medicines.org.uk/emc/product/6202/smpc
   Google Scholar
• Jost WH, Benecke R, Hauschke D, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:1913–1926. PMID: 25897202; PMCID: PMC4389813.
   PubMed Web of Science ®Google Scholar
• Lorenc ZP, Kenkel JM, Fagien S, et al. IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing. Aesthet Surg J. 2013;33(1_Supplement):S18–S22. PMID: 23515195.
   Google Scholar
• Ferrari A. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018Jan/Mar;33(1):7–18. PMID: 29633692; PMCID: PMC5901944.
   PubMed Web of Science ®Google Scholar
• Pellett S, Bradshaw M, Tepp WH, et al. The light chain defines the duration of action of botulinum toxin serotype A subtypes. mBio. 2018;9(2):e00089–18. PMID: 29588398; PMCID: PMC5874905.
   PubMed Web of Science ®Google Scholar
• Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002;96(1–2):105–113. PMID: 11755789.
   PubMedGoogle Scholar
• Hefter H, Brauns R, Ürer B, et al. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study. J Neurol. 2020;267(5):1340–1347. Epub 2020 Jan 20. PMID: 31960136; PMCID: PMC7184051.
   PubMed Web of Science ®Google Scholar
• Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology. 2020;94(20):e2109–e2120. Epub 2020 Apr 24. Erratum in: Neurology. 2020;95:802. PMID: 32332130.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48–e54. Epub 2018 Nov 21. PMID: 30464031.
   PubMed Web of Science ®Google Scholar
• Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67(5):669–683. PMID: 17385940.
   PubMed Web of Science ®Google Scholar
• Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol. 2002;27(1):18–22. PMID: 12160968.
   PubMed Web of Science ®Google Scholar
• Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112(1):73–81. PMID: 11802042.
   PubMed Web of Science ®Google Scholar
• Ellies M, Rohrbach-Volland S, Arglebe C, et al. Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatrics. 2002;33(6):327–330. PMID: 12571790.
   PubMed Web of Science ®Google Scholar
• Savarese R, Diamond M, Elovic E, et al. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil. 2004;83(4):304–311; quiz 312–314, 336. PMID: 15024333;
   PubMed Web of Science ®Google Scholar
• Banerjee KJ, Glasson C, O’Flaherty SJ. Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol. 2006;48(11):883–887. PMID: 17044954.
   PubMed Web of Science ®Google Scholar
• Gerlinger I, Szalai G, Hollódy K, et al. Ultrasound-guided, intraglandular injection of botulinum toxin A in children suffering from excessive salivation. J Laryngol Otol. 2007;121(10):947–951. Epub 2007 Mar 29. PMID: 17391573.
   PubMed Web of Science ®Google Scholar
• Ong LC, Wong SW, Hamid HA. Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A. J Pediatr Neurol. 2009;7:141–145.
   Google Scholar
• Hassin-Baer S, Scheuer E, Buchman AS, et al. Botulinum toxin injections for children with excessive drooling. J Child Neurol. 2005;20(120–3):120–123. PMID: 15794177.
   PubMedGoogle Scholar
• Jongerius PH, Rotteveel JJ, van Limbeek J, et al. Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology. 2004;63(8):1371–1375. PMID: 15505151.
   PubMed Web of Science ®Google Scholar
• Jongerius PH, van den Hoogen FJA, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004;114(3):620–627. PMID: 15342830.
   PubMed Web of Science ®Google Scholar
• Lin YC, Shieh JY, Cheng ML, et al. Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy. Neurology. 2008;70(4):316–318. PMID: 18209205.
   PubMed Web of Science ®Google Scholar
• Reid SM, Johnstone BR, Westbury C, et al. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008;50(2):123–128. PMID: 18201301.
   PubMed Web of Science ®Google Scholar
• Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg. 2009;111(1):79–82. Epub 2008 Nov 1. PMID: 18977585.
   PubMed Web of Science ®Google Scholar
• Møller E, Pedersen SA, Vinicoff PG, et al. Onabotulinumtoxin A treatment of drooling in children with cerebral palsy: a prospective, longitudinal open-label study. Toxins (Basel). 2015;7(7):2481–2493. PMID: 26134257; PMCID: PMC4516924.
   PubMed Web of Science ®Google Scholar
• Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics. 2008;39(4):200–204. Epub 2009 Jan 22. PMID: 19165707.
   PubMed Web of Science ®Google Scholar
• Schroeder AS, Kling T, Huss K, et al. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence. Neuropediatrics. 2012;43(1):27–36. Epub 2012 Mar 19. PMID: 22430158.
   PubMed Web of Science ®Google Scholar
• Taib BG, Williams SP, Sood S, et al. Treatment of sialorrhoea with repeated ultrasound-guided injections of botulinum toxin A into the parotid and submandibular glands. Br J Oral Maxillofac Surg. 2019;57(5):442–448. Epub 2019 Apr 19. PMID: 31010597.
   PubMed Web of Science ®Google Scholar
• Wu KP, Ke JY, Chen CY, et al. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011;26(7):838–843. Epub 2011 May 6. PMID: 21551374.
   PubMed Web of Science ®Google Scholar
• Scheffer AR, Erasmus C, van Hulst K, et al. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg. 2010;136(9):873–877. PMID: 208556Ne79.
   PubMedGoogle Scholar
• Erasmus CE, Scheffer AR, van Hulst K, et al. Does motor performance matter in botulinum toxin efficacy for drooling? Pediatr Neurol. 2011;45(2):95–99. PMID: 21763949.
   PubMed Web of Science ®Google Scholar
• Erasmus CE, van Hulst K, Scheffer AR, et al. What could predict effectiveness of Botulinum Toxin to treat drooling: a search for evidence of discriminatory factors on the level of body functions or structures. Eur J Paediatr Neurol. 2012;16(2):126–131. Epub 2011 Jul 23. PMID: 21783393.
   PubMed Web of Science ®Google Scholar
• Proveca Limited. Sialanar 320 micrograms/ml Glycopyrronium (400 micrograms/ml Glycopyrronium Bromide) Oral Solution. Summary of prescribing information. 2020. [cited 2021 May 19]. Available at: https://www.medicines.org.uk/emc/medicine/32715]
   Google Scholar
• Merz Pharmaceutical LLC. CUVPOSA (glycopyrrolate) oral solution. 2018. Prescribing information. [cited 2021 May 27]. Available at: https://www.cuvposa.com/wp-content/themes/cuvposa/assets/cuvposa-prescribing-information.pdf.
   Google Scholar
• Berweck S, Bonikowski M, Kim H, et al. Safety of incobotulinumtoxinA in the treatment of 6-17-year-old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Poster presented at TOXINS 2021 Virtual Conference; 16–17 January 2021.
   Google Scholar
• Banach M, Kaňovský P, Schroeder AS, et al. Safety of incobotulinumtoxinA in multipattern treatment of upper- and lower-limb spasticity in children/adolescents with cerebral palsy: a pooled analysis of 3 large phase 3 studies. Toxicon. 2021;190(Suppl 1):S7.
   Google Scholar